<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7366108\results\search\country\results.xml">
  <result pre="baffling pneumonia secondary to an unknown virus emerged in Wuhan," exact="China" post="in December 2019, and later the virus was identified"/>
  <result pre="intensive care [[7], [8], [9]]. A most recent report from" exact="China" post="CDC showed that 25% of patients have pre-existing comorbidities"/>
  <result pre="patients develop neurological symptoms [49]. Recently reports from UK and" exact="China" post="documented that COVID-19 patients showed convulsions, delirium, altered consciousness,"/>
  <result pre="Guillain-Barre syndrome (GBS) associated with COVID-19 was firstly reported in" exact="China" post="with manifestations, including leg weakness, and severe fatigue. It"/>
  <result pre="April 2020, a study from around 25 different hospitals in" exact="China" post="has been published with clinical records of pregnant women"/>
  <result pre="for treatment of influenza A and influenza B flu in" exact="Japan" post="and in the United States Chinese Clinical Trial Registry:(CHiCTR2000029544),"/>
  <result pre="influenza A and influenza B flu in Japan and in" exact="the United States" post="Chinese Clinical Trial Registry:(CHiCTR2000029544), (CHiCTR2000029548) 2. Favipiravir Broad-spectrum antiviral"/>
  <result pre="A and influenza B flu in Japan and in the" exact="United States" post="Chinese Clinical Trial Registry:(CHiCTR2000029544), (CHiCTR2000029548) 2. Favipiravir Broad-spectrum antiviral"/>
  <result pre="including coronaviruses Favipiravir is approved for treatment of influenza in" exact="Japan" post="National Clinical Trial Identifier:(NCT04336904), (NCT04349241), (NCT04336904), (NCT04346628), (NCT04310228), (NCT04319900),"/>
  <result pre="is an antiviral treatment used for influenza infection used in" exact="Russia" post="and China. National Clinical Trial Identifier:(NCT04252885), (NCT04260594)Chinese Clinical Trial"/>
  <result pre="Plasma from Recovered COVID-19 Donors Hackensack Meridian Health, New Jersey," exact="United States" post="Phase II(55) On-going NCT04343755 2. Convalescent Plasma from Recovered"/>
  <result pre="3. Convalescent Plasma from Recovered COVID-19 Donors Cristina AvendaÃ±o SolÃ¡," exact="Spain" post="Phase II(278) On-going NCT04345523 4. Convalescent Plasma from Recovered"/>
  <result pre="from Recovered COVID-19 Donors Centro de HematologÃ­a y Medicina Interna," exact="Mexico" post="Phase II(10) On-going NCT04357106 6. Convalescent Plasma from Recovered"/>
  <result pre="Convalescent Plasma from Recovered COVID-19 Donors University of Chicago, Illinois," exact="United States" post="Phase I(10) On-going NCT04340050 7. Anti-SARS-CoV-2 Inactivated Convalescent Plasma"/>
  <result pre="recovered from COVID-19 Donors Shanghai Public Health Clinical Center, Shanghai," exact="China" post="Observational Study(15) On-going NCT04292340 8. Convalescent Plasma from Recovered"/>
  <result pre="COVID-19 Donors Institute of Liver and Biliary Sciences, New Delhi," exact="India" post="Phase II(20) Completed NCT04346446 9. Convalescent Plasma Therapy on"/>
  <result pre="on Critically ill Novel Coronavirus (COVID-19) Patients Alkarkh Health Directorate-Baghdad." exact="Iraq" post="Interventional study(49) Completed NCT04441424 10. Effectiveness of Convalescent Immune"/>
  <result pre="Convalescent Immune Plasma Therapy Bagcilar Training and Research Hospital, Istanbul," exact="Turkey" post="Interventional study(60) Completed NCT04442958 7 Vaccines currently in clinical"/>
  <result pre="NCT04380701 6. Pathogen-specific aAPC; Subcutaneously Shenzhen Geno-Immune Medical Institute, Guangdong," exact="China" post="Phase I(100) On-going NCT04299724 7. Lentiviral Minigene Vaccine (LV-SMENP)"/>
  <result pre="(LV-SMENP) of Covid-19 Coronavirus; Subcutaneously Shenzhen Geno-Immune Medical Institute, Guangdong," exact="China" post="Phase I &amp;amp;II(100) On-going NCT04276896 8. BCG Vaccine for"/>
  <result pre="NCT04328441 9. SARS-CoV-2 Inactivated Vaccine Sinovac Biotech Co., Ltd., Jiangsu," exact="China" post="Phase I (Medium Dose, 144)Phase II (High Dose, 600)"/>
  <result pre="BCG Vaccine for Covid-19; Intradermally Murdoch Children's Research Institute, Victoria," exact="Australia" post="Phase III(4170) On-going NCT04327206 11. Coronavirus Disease (COVID-19) vaccineChAdOx1"/>
  <result pre="NCT04327206 11. Coronavirus Disease (COVID-19) vaccineChAdOx1 nCoV-19 University of Oxford," exact="United Kingdom" post="Phase I &amp;amp; II(1090) Completed NCT04324606 12. Investigating a"/>
  <result pre="NCT04324606 12. Investigating a Vaccine Against COVID-19 University of Oxford," exact="United Kingdom" post="Phase II &amp;amp; III(10260) On-going NCT04400838 13. Biological: Recombinant"/>
  <result pre="Inc.Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of" exact="China" post="Phase II(508) On-going NCT04341389 15. Evaluation of the Safety"/>
  <result pre="Journal of Pathology: A Journal of the Pathological Society of" exact="Great Britain" post="and Ireland203200463163710.1002/path.1570 14JaimesJ.A.WhittakerG.R.Feline coronavirus: insights into viral pathogenesis based"/>
  <result pre="function injury in 250 patients with severe acute respiratorv syndrome." exact="China" post="Journal of Modern Medicine 14, 121â€&quot;123. 61Jiang, T. J.,"/>
  <result pre="of liver injury in patients with severe acute respiratory syndrome." exact="China" post="Journal of Modern Medicine, 2004, 46. 62FarcasG.A.PoutanenS.M.MazzulliT.WilleyB.M.ButanyJ.AsaS.L.KainK.C.Fatal severe acute"/>
  <result pre="SARS-CoV-2 infection and virus load in fecal samples from the" exact="Hong Kong" post="cohort and systematic review and meta-analysisGastroenterology202010.1053/j.gastro.2020.03.065 71PetrieJ.R.GuzikT.J.TouyzR.M.Diabetes, hypertension, and"/>
 </snippets>
</snippetsTree>
